Autonomix Medical (Nasdaq:AMIX) announced that it received a new patent titled controlled sympathectomy and micro-ablation systems and methods. U.S. Patent No. 12,257,071 (‘071 patent) relates to advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation. The technologies provide enhanced precision in treating nerve-related conditions. The Woodlands, Texas-based Autonomix said its systems enable the […]
Autonomix Medical
Nerve ablation tech developer Autonomix to effect a reverse stock split
Autonomix (Nasdaq:AMIX) announced today that it filed to effect a 1-for-20 reverse stock split of its common stock. The Woodlands, Texas-based Autonomix plans for the split to take effect at 11:59 p.m. ET on Oct. 24, 2024. It plans for its common stock to open trading on the Nasdaq market on Oct. 25, 2024, on a […]
Autonomix licenses nerve ablation tech from RF Innovations
Autonomix Medical (Nasdaq:AMIX) announced today that it entered into a definitive licensing agreement with RF Innovations. The agreement enables Autonomix to license the intellectual property to RF Innovations’ Apex 6 radiofrequency (RF) generator. RF Innovations’ FDA-cleared Apex 6 lesions neural tissue for pain management in the peripheral nervous system. Autonomix expects to close the transaction […]
Cancer ablation tech company Autonomix has a new CEO
Autonomix Medical (NASDAQ:AMIX) announced that it appointed Brad Hauser as its new president and CEO, effective immediately. The Woodlands, Texas-based company appointed Lori Bisson, who previously held those positions, to executive vice chair of the board. Her role includes continuing to guide the company forward on corporate and capital markets strategies. Hauser brings more than […]
Autonomix completes first procedures in pancreatic cancer ablation trial
Autonomix Medical announced today that it completed the first three patient procedures in a proof-of-concept trial of its ablation technology. The Woodlands, Texas-based Autonomix designed its transvascular radiofrequency (RF) ablation technology to treat pancreatic cancer pain. Current approaches to treat this pain include opioids or ethanol injections. However, Autonomix says those approaches may only provide […]
Autonomix completes preclinical transvascular ablation study to treat pancreatic cancer
Autonomix Medical announced today that it completed an animal safety study evaluating its proprietary ablation technology. The Woodlands, Texas-based company designed its tissue ablation technology to address pancreatic cancer-related pain. Current approaches, like opioids or ethanol injections, may only provide limited relief and may lead to risky side effects. The company hopes its proof-of-concept effort […]
